CAN A NEW DEVELOPMENT MODEL PREVENT COSTLY PHASE III DRUG DEVELOPMENT FAILURES? by Dan Dupuis
Attaining FDA approval for a new drug is certainly the ultimate goal of any drug research initiative. Accelerating that process can not only prove to be beneficial to patients, but is also a key component of increasing the return on investment for any entity that has a vested interest in a new medication. Read More…
HOW NEW DEVELOPMENT MODELS CAN LEAD TO CANCER BREAKTHROUGHS by Dan Dupuis
The pharmaceutical industry’s long and successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters, worked well for many years, but its R&D productivity has now plummeted and the environment is changing. Read More…